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ALDHa b s t r a c t
Fibulin-3 (FBLN-3) has been postulated to be either a tumor suppressor or promoter depending on the
cell type, and hypermethylation of the FBLN-3 promoter is often associated with human disease, espe-
cially cancer. We report that the promoter region of the FBLN-3 was signiﬁcantly methylated (>95%) in
some pancreatic cancer cell lines and thus FBLN-3 was poorly expressed in pancreatic cancer cell lines
such as AsPC-1 and MiaPaCa-2. FBLN-3 overexpression signiﬁcantly down-regulated the cellular level
of c-MET and inhibited hepatocyte growth factor-induced c-MET activation, which were closely associ-
ated with c-radiation resistance of cancer cells. Moreover, we also showed that c-MET suppression or
inactivation decreased the cellular level of ALDH1 isozymes (ALDH1A1 or ALDH1A3), which serve as can-
cer stem cell markers, and subsequently induced inhibition of cell growth in pancreatic cancer cells.
Therefore, forced overexpression of FBLN-3 sensitized cells to cytotoxic agents such as c-radiation and
strongly inhibited the stemness and epithelial to mesenchymal transition (EMT) property of pancreatic
cancer cells. On the other hand, if FBLN3 was suppressed in FBLN-3-expressing BxPC3 cells, the results
were opposite. This study provides the ﬁrst demonstration that the FBLN-3/c-MET/ALDH1 axis in pancre-
atic cancer cells partially modulates stemness and EMT as well as sensitization of cells to the detrimental
effects of c-radiation.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Recent studies have suggested that increased aldehyde dehy-
drogenase (ALDH), which represents a family of evolutionarily
conserved enzymes localized in the nucleus, cytoplasm, and
mitochondria, is a key feature of cancer stem cells (CSCs) that is
measurable by the ALDEFLUOR assay [1,2]. The assay was origi-
nally used for the isolation of hematopoietic stem cells and is
now successfully and universally used to isolate CSCs of many can-
cers, including those of the lung, prostate, colon and pancreatic
cancer [3–5]. Importantly, identifying speciﬁc ALDH isoforms
prevalent in certain cancer types may have critical prognosticapplicability. Among 19 ALDH isoforms expressed in human,
ALDH1A1 was reported to be responsible for the ALDH activity of
pancreatic CSCs [6]. A more recent experiment with human breast
CSCs indicated that other ALDH isoforms, particularly ALDH1A3,
signiﬁcantly contribute to ALDEFLUOR positivity, which may be
tissue and cancer speciﬁc [7]. In addition, ALDH4A1 or ALDH7A1
is prevalent in other breast cancer cell types or in prostate cancer
cells [7,8]. Therefore, quantiﬁcation of prevalent ALDH isoforms
and identiﬁcation of their controlling signal pathway are required
for potential prognostic or therapeutic applications.
Fibulin-3(FBLN-3) is a secreted extracellular matrix glycopro-
tein, which is characterized by repeated epidermal growth fac-
tor-like domains. Recent studies have yielded conﬂicting results
regarding the role of FBLN-3 in cancer biology, showing either
tumor-suppressive or oncogenic behavior depending on the cancer
type. In glioma and pancreatic cancer, FBLN-3 overexpression was
associated with poor prognosis because of malignant cell growth
[9–11]. On the other hand, reduced FBLN-3 caused by FBLN-3
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and lung, breast, and prostate cancers and are associated with
worse prognosis [12–16].
In pancreatic cancer cells, chemo- and radioresistance are more
prevalent compared with other cancer cell types; these character-
istics are contributed by CSCs. Some studies have explored the
functional role of ALDH1 or c-MET as a novel marker for pancreatic
CSCs [17,18]. In this study, in spite of previous reports that FBLN-3
overexpression promotes cancer metastasis, angiogenesis, and
tumor growth [10,11], we ﬁrst investigated whether FBLN-3 gene
silencing is associated with poor prognosis in some pancreatic can-
cer cell lines, which are highly methylated in the FBLN-3 promoter
region. Moreover, we also showed that FBLN-3 inhibited c-MET
activation and gene expression, and this FBLN-3/c-MET axis also
negatively regulated cellular levels of ALDH1 isoforms, ALDH1A1
and ALDH1A3, which have been linked to the ‘‘stemness’’ charac-
teristics of CSCs.2. Materials and methods
2.1. Cell culture and irradiation
Human pancreatic cancer cell lines (AsPC1, BxPC3 and Mia-
PaCa2) were obtained from American Type Culture Collection
(ATCC, Manassas, VA, USA). Cell lines were grown in RPMI-1640
medium supplemented with 10% fetal bovine serum (FBS)
(Hyclone Lab, Logan, UT, USA) and penicillin/streptomycin. The
MiaPaCa2 cell line was maintained in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% FBS and penicillin/strep-
tomycin. Cells were incubated at 37 C in a humidiﬁed atmosphere
with 95% air/5% CO2. Cells were inoculated at a density of 1  105 -
cells in a T-25 ﬂask, incubated for 1 day, and then irradiated with a
total dose of 6 Gy from a 60Co c-ray at a rate of 0.5 Gy/min.
2.2. cDNA synthesis and PCR ampliﬁcation (FBLN-3, ALDH1A1,
ALDH1A3, c-MET)
Total RNA was isolated from cancer cells using RNA extraction
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and ﬁrst-strand com-
plementary DNA (cDNA) was synthesized from the total RNA (1 lg)
using a cDNA synthesis kit (Intron Biotechnology, Gyungki-do,
Korea). Resultant cDNAs served as templates for polymerase chain
reaction (PCR) ampliﬁcationwith the following forward and reverse
primers: FBLN-3-forward, 50-ATGTTGAAAGCCCTTTTCC-30; FBLN-3-







GAGGCC-30; b-actin-forward, 50-ATGTG CAAGGCCCGCTTCG-30;
b-actin-reverse, 50-TTAATGTCACGCACGATTTCC. The PCR conditions
were as follows: denaturating at 94 C for 5 min, followed by 30
cycles at 94 C for 1 min, and then at 58 C for 1 min and 72 C for
1 min 30 s, with a ﬁnal extension at 72 C for 10 min. The ampliﬁed
PCR productswere analyzed by agarose gel (1%; Intron Biotechnology)
electrophoresis. FBNL3 expression vectorwas constructed according
to the previous methods [13].
2.3. Western blot analysis
Western blot analysis was performed with primary antibodies
speciﬁc for human FBLN-3, p-c-MET, c-MET and Twist (Santa Cruz
Biotechnology, Dallas, TX, USA); Oct4 (Millipore, Billerica, MA,USA); E-cadherin, Sox2 and b-actin (Cell Signaling Technology,
Beverly, MA, USA); N-cadherin (BD Biosciences, San Jose, CA,
USA); and Snail, ALDH1A1 and ALDH1A3 (Abcam, Cambridge,
UK). Protein concentration was determined with a protein assay
(Bio-Rad, Hercules, CA, USA). Equal amounts of protein were sepa-
rated on a 10–15% sodium dodecyl sulfate-polyacrylamide gel and
transferred to a nitrocellulose membrane (Hybond; Amersham
Pharmacia, Pittsburgh, PA, USA). The blots were blocked for 1 h
at room temperature with blocking buffer (10% nonfat milk in
phosphate-buffered saline [PBS] containing 0.1% Tween 20 [TBS]).
The membrane was incubated overnight in a cold chamber with
speciﬁc antibodies. After being washed with TBS, the membrane
was incubated with a horseradish peroxidase-labeled secondary
antibody and visualized with the Westzol enhanced chemilumi-
nescence detection kit (Intron Biotechnology).
2.4. Silencing RNA targeting of FBLN-3 and c-MET
Cells were transfected with Stealth™ RNA targeting FBLN-3 and
c-MET (Invitrogen; primer sequences: FBLN-3; 50-CCUUGUCAAG-
AUCCCUACAUUCUAA-30/50-UUAG AAUGUAGGGAUCUUGACAAGG-30,
c-MET; 50-CCAUUUCAACUGAGUUUGCU GUUAA-30/50-UUAACAGC-
AAACUCAGUUGAAAUGG-30) or with Stealth™ RNAi Negative
Control Medium GC (Invitrogen) at a concentration of 80 nM of
Lipofectamine™ RNAi MAX reagent (Invitrogen). The cells were
incubated for 72 h after transfection, and then FBLN-3 and c-MET
expression was determined by RT-PCR.
2.5. Flow cytometric analysis
Cells were stained with the ALDEFLUOR reagent system (STEM-
CELL Technologies, Vancouver, BC, Canada) to characterize popula-
tions of ALDH-positive cells according to the manufacturer’s
instructions. Brieﬂy, Cells (1  106) were resuspended in ALDEFLU-
OR assay buffer containing the ALDH substrate in the presence or
absence of the ALDH inhibitor, diethylaminobenzaldehyde. Follow-
ing 30 min incubation at 37 C, the cells were washed. The ALDH
content was measured with a FACScan (Cytomics FC 500; Beckman
Coulter Counter, Fullerton, CA, USA). A minimum of 50,000 cells
were counted for each sample.
2.6. Colony-forming assay
For the colony-forming assay, cells were plated in 35-mm cul-
ture dishes at a density of 1000 cells per plate and allowed to
attach overnight. Cells were incubated for 10–14 days post-irradi-
ation and stained with 0.5% crystal violet. Colonies, deﬁned as
groups with P50 cells, were counted. Clonogenic survival was
expressed as a percentage relative to the untreated controls.
2.7. Sodium bisulﬁte modiﬁcation
Bisulﬁte-modiﬁed genomic DNA (gDNA) was prepared with the
EZ DNA Methylation-Gold Kit (Zymo Research, Orange, CA, USA).
The bisulﬁte reaction was carried out on 400 ng of gDNA, the reac-
tion volume was adjusted to 20 lL with sterile water, and 130 lL
of CT Conversion Reagent was added. The sample tubes were
placed in a thermal cycler (MJ Research, Waltham, MA, USA) and
the following steps were performed: 10 min at 98 C and 2 h
30 min at 64 C, and then storage at 4 C. The resultant DNA was
puriﬁed with the reagent provided in the EZ DNA Methylation-
Gold Kit. The converted samples were added to a Zymo-Spin IC™
column containing 600 lL of Zymo M-Binding Buffer and mixed
by inverting the column several times. The columnwas centrifuged
for 30 s and the ﬂow discarded. The column was washed by adding
200 lL of Zymo M-Wash Buffer and centrifuged at full speed; then
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umn, followed by incubation at room temperature for 15–20 min.
After incubation, the column was centrifuged at full speed for
30 s. The column was washed by adding 200 lL M-Wash Buffer
and centrifuged at full speed. The converted gDNA was eluted by
adding 20 lL of Zymo M-Elution Buffer into the column. The
DNA samples were ﬁnally stored at 20 C until further use.2.8. Pyrosequencing analysis
PCR was performed in a volume of 50 lL with 620 ng of con-
verted gDNA, 5 lL of 10 Taq buffer, 5 U of Hot/Start Taq polymer-
ase (Enzynomics, Daejeon, Korea), 4 lL of each 2.5 mM
deoxynucleoside triphosphate mixture, 2 lL of 10 pmol/lL Pri-
mer-S, and 2 lL of 10 pmol/lL biotinylated Primer-As. The ampli-
ﬁcation was performed according to the general guidelines
suggested for pyrosequencing: denaturing at 95 C for 15 min, fol-
lowed by 45 cycles at 95 C for 40 s, and then at 55 C for 40 s and
72 C for 40 s, followed by a ﬁnal extension at 72 C for 10 min. PCR
(5 lL) was conﬁrmed by electrophoresis in a 3% agarose gel and
visualized by ethidium bromide staining. A single-strand DNA tem-
plate was prepared from 20–25 lL of the biotinylated PCR product
with the use of streptavidin Sepharose HP beads (Amersham Bio-
sciences, Uppsala, Sweden) following the PSQ 96-sample prepara-
tion guide (Biotage, Charlottesville, VA, USA) using multichannel
pipettes. Then, 15 pmol of the respective sequencing primer set
was added for analysis. Sequencing was performed on a PyroMark
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Fig. 1. Pyrosequencing of four CpG islands on the FBLN-3 gene. (A) RT-PCR and Western
sequence of FBLN-3 gene and bisulﬁte-converted sequences. Each Y shown in the re
pyrosequencing in each cell lines. Each gray-colored box indicates the position of the four
The set of last bars indicates the means of all the methylated positions, 1–4.the manufacturer’s instructions without further optimization. The
methylation percentage was calculated as the average of the
degree of methylation at four CpG sites formulated during pyrose-
quencing [19].3. Results
3.1. Methylation analysis of CpG islands in the promoter region of
FBLN-3 in pancreatic cancer cell lines
Previous investigations have shown that many pancreatic can-
cer cells are notorious for their resistance to chemotherapy and
radiotherapy [20,21]. This characteristic results in poor therapeutic
efﬁciency. In the current study, we investigated whether FBLN-3 is
involved in cell resistance and stamens in the pancreatic cancer
cell lines. First, we showed by RT-PCR and Western blot analysis
that expression of the FBLN-3 scarcely occurred in the pancreatic
cancer cell lines AsPC1 and MiaPaCa2 compared with FBLN-3–
expressing H460 cells, in which signiﬁcant cellular levels of
FBLN-3 were detected (Fig. 1A). To investigate the involvement of
epigenetic modiﬁcation on FBLN-3 expression, we analyzed the
methylation pattern of FBLN-3 using the bisulﬁte pyrosequencing
method. Each primer was designed with the PSQ assay design pro-
gram (Biotage); the sequences of primers are listed in Fig. 1B. We
selected four CpG sites (positions 1 to 4) as shown in Fig. 1B and
prepared bisulﬁte-modiﬁed gDNA using the EZ DNA Methylation-
Gold Kit as noted in Section 2. The Y sequence (depicted as boxes)
shows the methylated sites in the pancreatic cancer cell lines inin3 
ucleotides)
ard primer : 5’-TGGATTTTATAGGAGTTGGTTAGAAGT-3’
rse primer : 5’-ACCRCAACCCAAAATACCAAT-3’
encing primer : 5’-TTTATAGGAGTTGGTTAGAAG-3’
ence to analyze : TTGGGAYGTTGAGTAGTTTTAGGGGATYGTYGYGTTA
d position in Aspc1, Bxpc3 and/or MIA PaCa2 (position 1 to 4) 
TGGATTTTAT   AGGAGTTGGT  TAGAAGTTGG  GAYGTTGAGT  AGTTTTAGGG
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GGTTAGGTYG  TTYGTTYGAA   ATTGGTATTT   TGGGTTGYGG T 
onverted 
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blot analysis of FBLN-3 gene expression in pancreatic cancer cell lines. (B) Original
d character indicates the methylated positions in each cell line. (C) Diagram of
Y’s shown in panel (B). (D) Comparison of fractions at the methylated CpG positions.
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ylation percentage was calculated as the average degree of methyl-
ation at four CpG sites formulated during pyrosequencing. As
shown in Fig. 1C, methylation of CpG sites at all positions tested
was higher in pancreatic cancer cells in comparison with FBLN3-
expressing H460 cells, and the average extent of methylation was
95% or more in AsPC1 and MiaPaCA cell lines and approximately
30% in BxPC3 cell line (Fig. 1D).3.2. The FBLN-3 gene is associated with cell resistance and stemness
regulation in pancreatic cancer cells
In the fast-growing variant cell line of the COLO375 human pan-
creatic cancer cell, a few reports have shown that expressing FBLN-
3 promotes cell growth and metastasis [10,11]. Moreover, the
resistance of pancreatic cancer cells is contributed by CSCs
[21,22]. Therefore, in this study, to investigate whether the FBLN-
3 is involved in the signaling pathway for c-radiation resistance
and cell stemness in some pancreatic cancer cells, FBLN-3 was
overexpressed by expression vectors, and cell stemness and resis-
tance were evaluated by the colony-forming and spheroid forma-
tion assay. As shown in Fig. 2A, overexpression of the FBLN-3
strongly induced the inhibition of cell growth in pancreatic cancer
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Fig. 2. Comparison of cell stemness, cell cytotoxicity, and metastatic property in FBLN-3
suppressing pancreatic cancer cells. (B) Inhibition of cancer cell stemness by FBLN-3 ove
Oct4) were decreased by FBLN-3 overexpression in AsPC1 and MaiPaCa2 pancreatic cance
and suppressing cells using Matrigel analysis and Western blot assay of EMT marker
c-irradiation (single dose of 6 Gy).signiﬁcantly suppressed the expression of stemness markers such
as Sox2 and Oct4 and thus inhibited spheroid formation, which
implies that FBLN-3 suppresses the self-renewal activity of the
CSC subpopulation in pancreatic cancer cells (Fig. 2B). Moreover,
FBLN-3 overexpression inhibited invasion and migration, with
decreases of representative EMT markers such as snail and N-cad-
herin (Fig. 2C). The colony-forming assay also showed that forced
expression of the FBLN-3 also signiﬁcantly sensitized the cellular
response caused by a single dose of 6 Gy c-radiation (Fig. 2D). On
the other hand, FBLN-3 suppression with siRNA in BxPC3 cell
strengthened the cell growth, EMT property and c-radiation resis-
tance. This result indicates that resistance of pancreatic adenocar-
cinoma cells against c-radiation may partly result from
reinforcement of stemness by the very low expression level of
FBLN-3 via a high percentage of methylation at a CpG island.3.3. FBLN-3 partially regulated c-MET activation and cellular level of
c-MET and ALDH1
To identify downstream targets that mediated cell stemness
and cell resistance functions of the FBLN-3 gene in pancreatic can-
cer cells, we used RT-PCR analysis to investigate expression levels
of ALDH1 and c-MET, which are representative genes related to cell
stemness and resistance in pancreatic cancer cells. ALDH1 andSox2 
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(Fig. 3A). The level of c-MET in AsPC 1 cell was much higher in pan-
creatic cancer cells than in A549 cells, which is a representative c-
radiation-resistant non-small cell lung cancer cell line. Moreover,
AsPC1 cells showed a high expression level of ALDH1 compared
with A549 cells through RT-PCR. In AsPC-1 and BxPC3 cell lines,
ALDH1A3 is the dominant isoform, and in MiaPaCa cells, both
ALDH1A1 and ALDH1A3 exist. We investigated whether FBLN-3
regulates the cellular level of ALDH1 isozymes and c-MET. FBLN-
3 overexpression in pancreatic cancer cells signiﬁcantly suppressed
the cellular level of c-MET (Fig. 3B). Moreover using RT-PCR analy-
sis and the ALDEFLUOR assay, we found that FBLN-3 signiﬁcantly
regulated the expression levels of ALDH1 isozymes, consequently
its activity. On the other hand FBLN-3 suppression in BxPC3 cells
increased cellular level of c-Met and ALDH activity (Fig. 3B and
C). Moreover, we ﬁrst showed that c-MET is associated with the
cellular ALDH1 level in pancreatic cancer cells. Blockage of c-MET
expression with siRNA or c-MET inactivation with inhibitor
(SU11274) resulted in a signiﬁcant reduction of Aldeﬂuor staining
and the expression of ALDH isoforms (ALDH1A1 and ALDH1A3) in
the c-MET–rich AsPC1 cell lines (Fig. 4A). In pancreatic cells, c-MET
activation (phosphorylation) by hepatocyte growth factor (HGF)
signiﬁcantly induced the expression of ALDH1 isoforms and thus
increased cellular ALDH1 activity (Fig. 4A). On the other hand
FBLN-3 overexpression suppressed an increase of cellular ALDH1
activity by inhibiting the HGF/c-MET activation axis, indicating
that FBLN-3 may function as inhibitor of HGF action (Fig. 4B and
C). This means that the chemo- and radioresistance of some pan-
creatic cancer cell lines partially results from the increased level
of c-MET and ALDH1 arising from a relatively scant level of FBLN-
3 expression caused by a relatively high percentage of DNA meth-
ylation at a CpG island. Taken together, these data suggest that the
FBLN-3/c-MET/ALDH1 axis is partially associated with the modula-
tion of stemness and EMT in pancreatic cancer cells and the
sensitization of cells to the detrimental effects of damaging agents.
4. Discussion
FBLN-3 is a member of the ﬁbulin family of an extracellular gly-
coprotein that is associated with the extracellular matrix. RecentA Lung cancer                Pancreatic cancer 
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Fig. 3. FBLN-3 negatively regulates ALDH and c-MET in pancreatic cancer cell lines. (A) R
cancer cell lines. (B) RT-PCR and Western blot analysis of ALDH isozymes and c-MET in
cells. (C) ALDEFLUOR assay of ALDH1 activity in FBLN-3 overexpressing or suppressing pﬁndings indicated that FBLN-3 is closely involved in tumor aggres-
siveness, functioning as a component of the tumor microenviron-
ment. There have been several reports about positive regulation of
cancer cell signaling by FBLN-3. FBLN-3 activated the Notch signal-
ing pathway in glioma and the EGFR-AKTpathway in pancreatic car-
cinoma cells [9,10]. In contrast, the FBLN-3 gene is expressed at a
very low level in invasive lung adenocarcinoma and HCC, which is
related to a poor prognosis. In lung adenocarcinoma and HCC, low
expression of the FBLN-3 gene is closely related to hypermethylation
of the promoter region [12,15]. Our study showed that forced
FBLN-3 overexpression in lung cancer cells exerts these effects by
inhibiting the PI3K/AKT/GSK3b pathway through IGF1R [13]. How-
ever, until now the involvement of low expression of FBLN-3 in
tumor aggressiveness has not been reported in pancreatic cancer
cells. Based on these, we investigated whether FBLN-3 is a negative
regulator in some pancreatic cancer cell lines. We conﬁrmed that
forced expression of FBLN-3 effectively inhibited the stemness and
EMT-related properties of pancreatic cancer cells. Furthermore,
we identiﬁed the signaling pathways inﬂuenced by FBLN-3.
The CSC model postulates that a small population of undifferen-
tiated tumorigenic cells is responsible for tumor initiation, propa-
gation, and spread to distant sites. The ﬁrst evidence of a role for
CSCs emerged from a study of human acute myeloid leukemia. In
this study, isolated CD34+/CD38 cells were identiﬁed as an acute
myeloma leukemia-initiating cell population and characterized as
CSCs; the hierarchy of CSCs mimicked the normal hierarchy of
hematopoietic stem cells [23]. In a stochastic model, cancer thera-
pies kill differentiated cells with limited replication potential and
thus shrink the bulk of the tumor. However, a small population
of cancer cells survives and acquires metastatic characteristics.
These metastatic cells are highly resistant to chemo- and radio-
therapy. Therefore, current chemotherapy regimens are usually
not effective against CSCs, and thus a number of therapies
targeting drug-resistant CSCs are currently under investigation. It
has been reported that the number of CSCs can increase after can-
cer therapy. In pancreatic cancer cells, gemcitabine treatment led
to an increase in the number of CD133+ cancer stem-like cells
[24]. Treatment of unsorted HCC cells with doxorubicin or
ﬂuorouracil in vitro signiﬁcantly enriched the number of CSCs
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Fig. 4. FBLN-3 regulates HGF-induced c-MET activation and ALDH level in pancreatic cancer cell lines. (A) RT-PCR, Western blot analysis, ALDEFLUOR assay and colony
forming analysis of c-MET inactivated AsPC1 cells using SU11274 inhibitor or siRNA. (B) c-MET activation and ALDH1 induction caused by HGF in pancreatic cancer cells were
suppressed by FBLN-3 overexpression. (C) ALDOFLUOR assay of MiaPaCa2 and FBLN-3-overexpressing MiaPaCa2 cells treated with HGF. HGF was treated about 2 h.
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selection of CSCs characterized by an increased percentage of
CD44+/CD24/low cells [26].
Cancer stemcellswithALDHenzymeactivity in colorectal cancer
were also enriched following treatmentwith anticancer drugs, such
as cyclophosphamide [27]. ALDH1has beenwidely used as amarker
for the identiﬁcation and isolation of CSCs. When 50,000 ALDH1
breast cancer cellswere transplanted intoNOD/SCIDmice, no tumor
formed, but 500 ALDH1+ cells were able to form a tumor [28]. This
ﬁnding strongly indicated that ALDH1+ cells have the characteristic
of tumor initiation (cancer stemcell like) and thus are highly tumor-
igenic. It has been shown that breast cancer patients with ALDH1+
tumors have a lower overall survival after cancer therapy because
ALDH1+ cells are more resistant to therapeutic agents such as c-
radiation. c-MET is also important for cell survival, resistance, and
metastatic ability. After c-MET was ﬁrst identiﬁed in the early
1980s, it was proposed that MET ampliﬁcation leads to geﬁtinib
(EGFR inhibitor) resistance in lung cancer by activating ERBB3 sig-
naling, suggesting c-MET as a potential therapeutic target and bio-
marker [29]. Furthermore, a recent study showed that MET
ampliﬁcation is a closely related characteristic of CSCs. Some studies
showed that c-MET activation in glioblastoma is a functional requi-
site for the CSC phenotype and a promising therapeutic target [30].
In pancreatic cancer cells, c-MET inhibition reduced the population
of CSCs and thus blocked the self-renewal capacity, along with pre-
venting the development of metastases [31]. Focusing on the
expression of FBLN-3, we concluded that the extent of methylation
of a CpG island in the FBLN-3 promoter, thus the expression level
of the protein, partially determined the stemness of pancreatic can-
cer cells through c-MET/ALDH1 regulation. This study provides the
ﬁrst demonstration that the FBLN-3/c-MET/ALDH1 axis modulates
cell stemness, metastasis, and sensitization of cells to the detrimen-
tal effects of damaging agents.
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